Superworth

Lifecore Biomedical price to book ratio LFCR

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
190×
Oct 2025
10-year median
1.6×
10-year range
0.7× to 196×
Peer median
2.2×

Lifecore Biomedical's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Oct 2025, at 190×.

On the days it had one over the last ten years, its median was 1.6×, from 0.7× in Mar 2023 to 196× in Sep 2025.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2025190×13.4×196×
202413.5×5.8×14.1×
20235.5×0.7×9.3×
20222.0×1.6×3.0×
20211.7×1.3×1.8×
20201.4×0.9×1.6×
20191.3×1.0×1.5×
20181.3×1.3×1.7×
20171.5×1.4×1.8×
20161.7×1.2×1.9×
20151.4×1.4×1.9×
20141.9×1.4×1.9×
20131.8×1.6×2.3×
20121.6×1.0×2.0×
20111.0×1.0×1.2×

Against its peers

Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.

CompanyPrice to book ratio
LFCRLifecore Biomedicaln/m
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
LFVNLifevantage2.2×
ABUSArbutus Biopharma3.2×
SPROSpero Therapeutics1.5×
Peer median2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Lifecore Biomedical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.